| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIAA1826 |
| Uniprot No | Q8NCY6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-345aa |
| 活性数据 | MKQLKRKRKSNFSVQETQTLLKEITKRKEVIFSKQLNTTINVMKRMAWEEIAQCVNAVGEGEQRTGTEVKRRYLDWRALMKRKRMKANIKLVGSGFPLPSSDLDDSLTEEIDEKIGFRNDANFDWQNVADFRDAGGSLTEVKVEEEERDPQSPEFEIEEEEEMLSSVIPDSRRENELPDFPHIDEFFTLNSTPSRSAYDEPHLLVNIEKQKLELEKRRLDIEAERLQVEKERLQIEKERLRHLDMEHERLQLEKERLQIEREKLRLQIVNSEKPSLENELGQGEKSMLQPQDIETEKLKLERERLQLEKDRLQFLKFESEKLQIEKERLQVEKDRLRIQKEGHLQ |
| 分子量 | 67.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人KIAA1826蛋白的模拟参考文献(基于当前科学背景生成，非真实文献)：
---
1. **文献名称**：*"Functional characterization of recombinant human KIAA1826 protein in glioma cell migration"*
**作者**：Li, X., et al.
**摘要**：研究通过体外重组表达KIAA1826蛋白，发现其通过调控MAPK信号通路促进胶质瘤细胞的迁移能力，提示其在癌症侵袭中的潜在作用。
---
2. **文献名称**：*"Crystal structure and ATPase activity of the KIAA1826 protein domain"*
**作者**：Yamamoto, T., & Suzuki, K.
**摘要**：首次解析了重组KIAA1826蛋白的ATP结合结构域晶体结构，并证实其具有ATP水解酶活性，为研究该蛋白的分子功能提供结构基础。
---
3. **文献名称**：*"KIAA1826 interacts with 14-3-3 proteins and promotes neuronal apoptosis"*
**作者**：Chen, H., et al.
**摘要**：通过免疫共沉淀实验验证KIAA1826与14-3-3蛋白家族的相互作用，并在神经元凋亡模型中观察到该蛋白的促凋亡功能，可能与神经退行性疾病相关。
---
4. **文献名称**：*"Recombinant KIAA1826 as a novel biomarker in hepatocellular carcinoma"*
**作者**：Wang, Y., et al.
**摘要**：基于ELISA检测发现，肝癌患者血清中KIAA1826蛋白水平显著升高，提示其可能作为肝癌早期诊断的新型生物标志物。
---
注：以上内容为模拟生成的参考文献，实际研究中建议通过PubMed、Web of Science等平台检索真实文献。
Recombinant human KIAA1826 protein, commonly known as Cancerous Inhibitor of PP2A (CIP2A), is a oncoprotein implicated in regulating cell proliferation and survival. Initially identified through genomic sequencing projects, the *KIAA1826* gene encodes a 90 kDa protein that interacts with the tumor suppressor protein phosphatase 2A (PP2A), inhibiting its activity. PP2A is critical for maintaining cellular homeostasis by dephosphorylating key signaling molecules, and its suppression by CIP2A promotes oncogenic signaling pathways, including RAS-MAPK and MYC. This interaction stabilizes oncoproteins like c-Myc and enhances Akt phosphorylation, driving cell cycle progression and resistance to apoptosis.
CIP2A is overexpressed in various cancers, such as leukemia, breast, lung, and gastric cancers, correlating with poor prognosis and therapeutic resistance. Its role in tumorigenesis has made it a potential biomarker and therapeutic target. Recombinant KIAA1826/CIP2A is typically produced in bacterial or mammalian expression systems for functional studies. Researchers use it to explore its biochemical interactions, structure-function relationships, and mechanisms underlying PP2A inhibition. Additionally, it aids in screening small-molecule inhibitors designed to disrupt CIP2A-PP2A binding, offering a strategy to restore PP2A activity in cancer cells. Structural studies highlight its N-terminal phosphatase-binding domain and C-terminal coiled-coil regions, essential for oligomerization and oncogenic function. Understanding CIP2A’s regulatory networks provides insights into cancer biology and precision medicine approaches.
×
